Context Therapeutics
@Context_Tx
Followers
477
Following
97
Media
136
Statuses
310
Advancing T Cell Engagers for Solid Tumors
Philadelphia, PA
Joined May 2018
Context acquired CT-95, a potentially first-in-class mesothelin x CD3 bispecific antibody. This is the second clinical-stage T cell engager for solid tumors in our pipeline. CT-95 is on track for Phase 1 initiation in the first quarter of 2025. $CNTX
1
1
3
Context Therapeutics $CNTX Q2 2025 Highlights:.✅ CTIM-76 & CT-95 Phase 1 dose-escalation trials ongoing.✅ $83.5M cash and cash equivalents as of June 30, 2025.✅ Expected cash runway into 2027. Read more here: #Biotech #Immunotherapy #CancerRes #TCE
0
1
3
$CNTX announces CTIM-76 Trial in Progress poster at #ASCO25.✅Dosing Cohort 3 of Phase 1 trial.✅ CLDN6 x CD3 TCE for ovarian, endometrial & testicular cancers.✅Initial data expected 1H 2026.📍Poster: June 2, Hall A, 1:30 PM CDT. 🔗 #Biotech.
contexttherapeutics.com
Summary of Context Therapeutics investigational medicines.
3
2
5
We’re excited to welcome Dr. Karen Chagin as Chief Medical Officer at $CNTX, effective June 9, 2025!. With 10+ years leading T cell therapy development at Adaptimmune and Tmunity, she brings deep clinical expertise at a key time for Context. Read more:
0
2
5
🚨 Context Therapeutics $CNTX Q1 2025 Highlights:.✅ CTIM-76 & CT-95 in Phase 1 trials.✅ $89.4M cash and cash equivalents as of March 31, 2025.✅ Expected cash runway into 2027.#Biotech #Immunotherapy #CancerResearch #TCellEngagers. Read more here:
ir.contexttherapeutics.com
CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027...
0
1
5
🚨 We’re excited to welcome Jennifer Dashnau, PhD, MBA as SVP of Technical Operations at Context Therapeutics!. Welcome to the team, Jennifer! 👏. #Biotech #Leadership #Immunotherapy #TCellEngagers #ContextTherapeutics #Oncology #WomenInSTEM
0
0
3
The Context team presented preclinical and translational data for CT-95, our mesothelin-targeting T cell engager, at #AACR2025! View the poster here: #Immunotherapy #Biotech $CNTX
0
0
6
📢 Context Therapeutics CEO Martin Lehr will join the T Cell Engagers panel at #AACR25!. 🗓 Thursday, April 24 | 🕠 5:45–6:45 PM CT | 📍 Room W192.Moderated by Leerink Partners, the panel includes leaders from J&J, Zymeworks.#Biotech #Immunotherapy #TCellEngagers.
0
0
0
🚀Another big milestone for $CNTX: First patient dosed in Phase 1 clinical trial of CT-95, our mesothelin x CD3 T cell engaging bispecific antibody targeting solid tumors. CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic in 2025 💡.#Immunotherapy.
0
1
4
Join $CNTX at two premier events! Catch our presentation on Tuesday, April 8 at 10 AM ET during the Stifel Virtual Targeted Oncology Forum, and meet us at the 24th Annual Needham Virtual Healthcare Conference with 1x1 meetings on April 8th #Biotech.
0
2
2
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors. Andy is the former EVP, Chief Strategy Officer of Horizon Pharma (acquired for $28Bn) and Senior Partner at Bain & Company.
6
0
2
Our CEO, Martin Lehr, will present at the Piper Sandler 36th Annual Healthcare Conference on December 4th at 11:00am ET. #PiperSandler, #oncology, T cell engager
2
0
1
Context Therapeutics to Participate in UBS, Guggenheim, and Stifel Investor Conferences in November.
globenewswire.com
PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing...
1
0
1
Context Therapeutics ($CNTX) announces poster presentation featuring CTIM-76, a CLDN6xCD3 T cell engager, at #SITC2024 on November 9th.
1
0
0
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize CT-202 (formerly BA3362), a Nectin-4 x CD3 T Cell Engaging Antibody. $CNTX, $BCAB
0
1
6
Our CEO Martin Lehr will participate in a fireside chat with Emily Bodnar, PhD and host one-on-one meetings at the H.C. Wainwright & Co., LLC investor conference on Sept. 9th. $CNTX, #HCW2024
0
0
3
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors. Karen and Luke bring extensive operational, clinical, and transactional experience to support corporate and pipeline strategy. $CNTX, TCE, #CLDN6
0
2
4